Kyle Bass Is ‘Frustrated’ by Shire’s Lialda Patent Ruling
- ‘The system must be fixed,’ hedge fund manager Bass says
- Bass criticizes drug prices, Shire’s Dublin headquarters
This article is for subscribers only.
Hedge fund manager Kyle Bass expressed frustration that the U.S. Patent and Trademark Office upheld the only patent covering Shire Plc’s colitis drug Lialda and argued that “the system must be fixed.”
The Patent Trial and Appeal Board within the agency on Wednesday rejected arguments by Bass’s Coalition for Affordable Drugs that the patent never should have been issued. The coalition had argued the patent covered old ideas.